Approved indications:

• Hyponatremia: treatment of clinically significant hypervolemic or euvolemic hyponatremia (serum sodium usually <125 mEq/L or symptomatic and resistant to fluid restriction), including cases due to heart failure and syndrome of inappropriate antidiuretic hormone (SIADH).
• ADPKD: slowing kidney function decline in adults at risk for rapidly progressing autosomal dominant polycystic kidney disease.

Off-label uses (evidence level):

• Some clinicians use tolvaptan off-label for chronic or milder SIADH-related hyponatremia and in certain hospital settings outside the strict label criteria; evidence comes mainly from small trials and observational studies rather than large outcome trials.
• Use as a routine diuretic for heart failure or cirrhosis is generally limited in the U.S. because outcome benefits over standard therapies have not been clearly proven.

Efficacy expectations – hyponatremia:

• Serum sodium often begins to rise within 4–8 hours of the first dose and typically improves over the first several days.
• Most patients experience a meaningful increase in sodium while on therapy, but levels tend to fall back toward baseline within about a week after stopping the drug.
• Compared with placebo, tolvaptan produces a larger and faster correction of sodium, but requires careful dosing and monitoring to avoid overly rapid correction.

Efficacy expectations – ADPKD:

• Tolvaptan does not cure ADPKD or reverse existing cysts, but it slows the rate at which kidney function (eGFR) declines and total kidney volume increases.
• Benefits are seen over years, with average slowing of eGFR loss by roughly 1 mL/min/1.73 m² per year compared with standard care in high-risk patients.
• It is generally more effective when started earlier in the course of rapidly progressive disease and taken consistently long term, though liver toxicity risk limits or stops therapy in some patients.

Typical dosing – hyponatremia (Samsca and generics):

• Adults usually start at 15 mg by mouth once daily, with possible increases to 30 mg and then 60 mg once daily, no more often than every 24 hours, based on sodium response and tolerability.
• Treatment duration is limited to 30 days because of liver safety concerns.
• Initiation and any re-initiation are done in the hospital so sodium and volume status can be closely monitored; the tablet can be taken with or without food, at about the same time each day.
• Fluid restriction is generally avoided during the first 24 hours to reduce the risk of overly rapid sodium correction; you should drink in response to thirst.

Typical dosing – ADPKD (Jynarque):

• Tolvaptan is taken twice daily: a higher dose on waking and a lower dose about 8 hours later.
• The usual starting total daily dose is 60 mg (45 mg in the morning and 15 mg later), which may be increased stepwise to 90 mg/day (60 mg + 30 mg) and then 120 mg/day (90 mg + 30 mg) as tolerated.
• Doses are individualized; patients are encouraged to drink enough water throughout the day to match urine losses and avoid dehydration.

Special dosing instructions:

• Strong CYP3A inhibitors (for example, certain azole antifungals, macrolide antibiotics, and some HIV medicines) are contraindicated because they greatly increase tolvaptan levels; moderate CYP3A inhibitors often require dose reductions.
• Strong CYP3A inducers (such as rifampin or some seizure medicines) can reduce effectiveness and are generally avoided.
• Grapefruit or grapefruit juice should be avoided, as it can increase blood levels of tolvaptan.
• For ADPKD, regular liver function testing on a strict schedule is required and therapy may be interrupted or stopped if abnormalities occur.

Missed-dose guidance:

• If a dose is missed, take the next scheduled dose at the usual time and do not double up to make up for the missed tablet.
• For twice-daily ADPKD dosing, if the later dose is missed, skip it if it is close to the time for the next morning dose and resume the regular schedule.

Overdose:

• Taking too much tolvaptan can cause excessive water loss, severe dehydration, high sodium levels, or liver injury, with symptoms such as confusion, extreme thirst, fainting, or irregular heartbeat.
• In case of suspected overdose, seek emergency medical care or contact a poison control center immediately; do not attempt to treat it by simply drinking large amounts of fluid without medical supervision.

Common side effects:

• Increased urination, needing to urinate at night, thirst, dry mouth, and increased fluid intake are very common and usually appear soon after starting treatment.
• Headache, fatigue, constipation, decreased appetite, and dry skin or eyes may occur and are generally mild to moderate.
• Because the drug makes you lose free water, dehydration and mild rises in sodium can occur if you do not drink enough; symptoms include dizziness, lightheadedness, or weakness.

Serious or rare adverse effects (seek urgent attention):

• Serious liver injury, including acute liver failure requiring transplant, has occurred, especially with long-term use for ADPKD; warning signs include unusual fatigue, loss of appetite, right upper abdominal pain, dark urine, yellowing of skin or eyes, or itching.
• Overly rapid correction of sodium can cause osmotic demyelination syndrome with confusion, trouble speaking or swallowing, behavior changes, difficulty walking, or seizures.
• Severe dehydration or hypernatremia (very high sodium) can lead to confusion, fainting, irregular heartbeat, or kidney injury.
• Allergic reactions such as rash, swelling, trouble breathing, or severe dizziness are medical emergencies.

Warnings and precautions:

• Age: safety and effectiveness are not established in children; use is restricted to adults.
• Liver disease: Jynarque carries a boxed warning for serious liver injury and requires regular liver blood tests; tolvaptan should be avoided or used with extreme caution in patients with significant underlying liver disease, and stopped if liver injury is suspected.
• Kidney disease: in ADPKD, tolvaptan is used specifically for chronic kidney disease, but is not recommended in anuric patients or those unable to respond with increased urine; for hyponatremia it is generally not used when creatinine clearance is extremely low (about <10 mL/min).
• Pregnancy: based on animal data, tolvaptan may harm the fetus; it is usually avoided during pregnancy, and women who can become pregnant typically should use effective contraception.
• Breastfeeding: it is not known if the drug passes into human milk; breastfeeding is not recommended while taking tolvaptan.
• Do not use if you cannot sense or respond to thirst, are severely dehydrated, cannot urinate, or already have very high sodium levels.

Comparative safety:

• Compared with older options for chronic hyponatremia (such as demeclocycline or long-term hypertonic saline), tolvaptan offers an effective oral option but carries unique risks of liver injury and intense water loss.
• Because of these risks, especially in ADPKD, use is restricted under a REMS program and requires regular lab monitoring, so it is generally reserved for patients who are most likely to benefit.

Side-effect reporting and safety updates:

• Patients should promptly report any bothersome or unusual symptoms to their prescriber or pharmacist, particularly signs of liver problems, neurologic changes, or severe dehydration.
• In the U.S., side effects can also be reported to the FDA through the MedWatch adverse event reporting program, and updated safety information is posted on the FDA’s drug safety communications pages.

Drug and food interactions:

• Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, certain HIV protease inhibitors) can greatly increase tolvaptan levels and are contraindicated.
• Moderate CYP3A inhibitors (such as diltiazem, verapamil, fluconazole, erythromycin) may require dose reduction and closer monitoring.
• Strong CYP3A inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) can decrease drug levels and reduce effectiveness, so they are generally avoided.
• Other diuretics, especially loop or thiazide diuretics, increase the risk of overly rapid sodium correction or dehydration when combined with tolvaptan and require careful monitoring.
• Concomitant use with desmopressin (a vasopressin V2 agonist) is avoided because tolvaptan blocks its effect.
• Alcohol can worsen dehydration and impair judgment about thirst; intake should be limited and discussed with the prescriber.
• Grapefruit and grapefruit juice inhibit CYP3A and should be avoided during therapy.

Precautions and conditions making use unsafe or higher risk:

• Significant liver disease or prior serious drug-induced liver injury, particularly for ADPKD treatment, increases the risk of severe hepatotoxicity.
• Inability to sense or respond to thirst, severe dehydration, anuria (no urine output), or very high baseline sodium are major contraindications.
• Use in pregnancy or while breastfeeding is generally avoided because of potential harm to the baby and lack of adequate human data.
• Patients with very advanced kidney failure who cannot produce urine are unlikely to benefit and may be harmed.

Monitoring needs:

• Serum sodium and other electrolytes, volume status, and neurologic status must be checked frequently when starting or adjusting therapy for hyponatremia to prevent too-rapid sodium shifts.
• For ADPKD, liver enzymes (ALT, AST) and bilirubin are measured before starting, at 2 and 4 weeks, monthly for the first 18 months, and then every 3 months, with additional tests if symptoms arise.
• Kidney function (eGFR, creatinine), body weight, blood pressure, and urine output are monitored regularly in all indications.
• Based on co-medications, additional lab tests (such as drug levels of interacting medicines) may be needed.

Q: How quickly will tolvaptan start to work for low sodium?
A: In many adults treated for hyponatremia, blood sodium begins to rise within the first 4–8 hours and continues to improve over several days, but the exact time and degree of response vary and require lab monitoring.

Q: Will tolvaptan cure ADPKD or stop cysts from growing?
A: No, tolvaptan does not cure ADPKD or remove existing cysts; it slows the rate at which cysts enlarge and kidney function declines, so disease still progresses but usually more slowly than without treatment.

Q: Why do I have to drink so much water while taking tolvaptan?
A: The medicine makes your kidneys excrete a lot of free water, so you need to drink regularly in response to thirst to prevent dehydration and high sodium levels, especially during the daytime hours after each dose.

Q: Can I drink alcohol while taking tolvaptan?
A: Occasional light alcohol use may be permitted for some patients, but alcohol can worsen dehydration and affect liver health, so you should discuss any alcohol use with your prescriber and follow their specific advice.

Q: What happens if I stop taking tolvaptan suddenly?
A: For hyponatremia, sodium levels typically drift back toward baseline within about a week after stopping, and for ADPKD, kidney function decline gradually returns to its usual (faster) rate, so any change in therapy should be planned with your clinician.

Q: Do I really need all the blood tests while on Jynarque for ADPKD?
A: Yes, regular blood tests—especially liver tests—are required because they help detect early signs of liver injury or other problems so treatment can be adjusted or stopped before serious harm occurs.

Storage:

• Store tablets at room temperature, away from excess heat and moisture, and keep them in their original container with the lid tightly closed.
• Keep out of reach of children and pets, and do not use tablets that are expired, discolored, or damaged.

Disposal:

• Use a local medicine take-back program if available, or ask your pharmacist about safe disposal options.
• If no take-back option exists, follow pharmacist or community guidance for mixing unused tablets with undesirable household material in a sealed container before discarding in the trash; do not flush unless specifically instructed.